The interleukin - 11 still is the main drugs increase platelet, is also the only fda-approved drugs listed the ascension of platelets.

The drug listing will fill the domestic blank, the market prospect is considerable. The current clinical anticoagulants are mainly composed of heparin.

重组人甲状旁腺素（rhPTH）开辟了治疗骨质疏松症的新疗法（骨同化治疗），对降低骨质疏松症患者椎骨骨折和非椎骨骨折的发生率优于现有治疗药物。预计到2020年我国骨质疏松和低骨量患者将增加至2.8亿。

My company's restructuring carboxypeptidase G2, only in new cases of the market, sales is expected to reach at least 1 billion yuan/year, potential market more than 5 billion yuan/year.